Breast tumors: an overview

Daniel Birnbaum, François Eisinger, Jocelyne Jacquemier, Michel Longy, Hagay Sobol, Charles Theillet

Laboratoire d'Oncologie Moléculaire, U.119 Inserm, Institut de Cancérologie et d'Immunologie de Marseille, 27 Bd. Lei Roure, 13009 Marseille, France (DB, FE, JJ, ML, HS, CT)

Published in Atlas Database: January 1999
Online updated version: http://AtlasGeneticsOncology.org/Tumors/breastID5018.html
DOI: 10.4267/2042/37518

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Classification
- Ductal adenocarcinoma is the most common;
- Lobular carcinoma is the second malignant breast tumour;
- Medullary carcinoma is rare;
- Hyperplasia is a proliferation without criteria of malignancy;
- Fibroadenomas are benign breast tumours.

Clinics and pathology

Epidemiology
The annual incidence of breast cancer is about 43/100 000 per year in France, and the mortality rate is about 18/100 000 per year; one million women worldwide are diagnosed with breast cancer every year.
The main factors of risk are:
- gender: women's risk is 400 times that of men's;
- age: mean age at diagnosis is around 60 yrs;
- genetic factors: rare (3 to 5% of cancers and 1/500-800 women) but highly predictive of the disease.

Pathology
- Ductal adenocarcinoma is the most common (80%) histological presentation of malignant breast tumor; it is a proliferation of epithelial cells from galactophoral ducts; it may be preceeded by an in situ carcinoma, characterized by a proliferation of cells within the ducts without interruption of the basal membrane; when this membrane is altered, the carcinoma is invasive.
- Lobular carcinoma is the second major type (5-10%); it may also be preceeded by an in situ stage which is rather a marker lesion than a true malignant one.
- Typical medullary carcinoma is a rare entity (1%) with a better prognosis, often with a familial background; it is well circumscribed, with a syncitial pattern, and a lymphoid infiltrate; atypical medullary carcinoma lacks some of these features.
- The different steps in the progression of breast cancer are not well individualized.
- Hyperplasia is a proliferation of ductal or lobular epithelial cells, without criteria of malignancy; in contrast, atypical hyperplasia has incomplete malignant features and can be difficult to distinguish from in situ carcinoma.
- Fibroadenomas are the most common form of benign breast tumors.
- These different forms of breast cancer may occur with (hereditary or familial forms) or without (sporadic forms) a familial background.

Prognosis
Upon diagnosis, the different presentations are classified upon morphological study, and the gravity and prognosis of the disease is estimated with several parameters that are:
- tumor size,
- tumor grade: it is calculated from assessment of tubular differentiation, number of mitoses, and nuclear polymorphism,
- the absence of estrogen and progesterone receptors,
- the presence of lymph node metastasis,
- peritumoral vascular invasion.
Other parameters such as the proliferating index (Ki 67, S-phase), the ploidy, and the presence of P53 or ERBB2 alteration may also be useful for prognostic evaluation or as predictive factors for therapeutic response.
Breast tumors: an overview

Genetics

Note
Familial breast cancers are thought to represent about 5 to 10% of all breast cancers.

Cytogenetics

Cytogenetics Morphological
Many of the chromosomal aberrations observed in breast carcinomas are not specific of this type of tumour; karyotypes of breast tumours frequently show multiclonality, suggesting the existence of a high degree of intratumoural heterogeneity.
Alterations of chromosome arms 1q, 3p, 6q, 8p are often present; i(1q) and der (1;16) are frequent as sole anomalies; +7, +8 and +20 are also frequent; cytogenetic signs of DNA amplification, such as homogeneously staining regions (HSR), are commonly observed in breast carcinomas and seem preferentially associated to 8p.

Cytogenetics Molecular
LOH studies: loss of heterozygosity (LOH) has been associated with physical deletion of large genomic segments containing tumour suppressor genes; common regions of LOH in breast cancer are located on several chromosomes: 1p, 1q, 3p, 6q, 8p, 11q, 13q, 16q, 17p, 17q; almost all breast tumours show LOH in one or several regions; some regions are lost in more than 50% of tumors; 8p, 16q, 17p; precancerous lesions also show LOH.
CGH: Comparative genomic hybridization (CGH) is a molecular cytogenetics method designed to detect and map chromosomal regions showing abnormal copy numbers in tumors; theoretically, it is possible to detect equally copy number gains (DNA amplification or polyploidies) or losses using this approach; it appears, however, that CGH has a greater sensitivity for gains than for losses; this could be related to the fact that gains are generally of higher magnitude than losses and that losses can be obscured by intratumoral heterogeneity;
Overall, CGH data show that breast tumor genomes undergo severe rearrangements; on average, breast tumors show 5-7 copy number changes/tumor; less than 10% of the tumors analyzed by CGH show neither gains nor losses; almost every chromosome presents at least one site with aberrant copy numbers, however, gains or losses are not evenly distributed throughout the genome.
Hot spots for gains are routinely observed at 1q (50-55% of the tumors), 8q (60%), 17q (25-30%), 20q (20-25%); gains generally involve subregions of each chromosomal arm and most prevalent regions are 1q31-q32, 8q12 and 8q24 (with MYC and other genes), 17q12 (ERBB2) and 17q23-q24, and 20q13; other regions of recurrent gains are 11q13 (20%, with CCND1), 8p12 (10-15%, and FGFR1), 16p (10-15%); recurrent losses are observed at 1p, 6q, 8p, 11q23-pter, 13q, 16q, 17p and 22q.
CGH has revealed that copy number gains are common in breast tumors and involve 26 (!) chromosomal arms; these data somewhat contradict karyotypical analysis and LOH studies which indicate that losses are more frequent that gains; furthermore, it appears from CGH data that the number of events (gains and losses) increases in advanced cancer.

Genes involved and proteins

HRAS (11p15.5), KRAS (12p12.1), NRAS (1p13.2)
Protein
H, K, and NRAS genes are a subfamily of the huge RAS/RHO/RAB superfamily and encode ubiquitous cytoplasmic GTP binding p21 proteins involved in signal transduction.

Somatic mutations
RAS genes are mutated at codons 12, 13 and 61 in different types of cancers; the frequency of mutations in breast cancer is rather low (<10%) compared to colorectal cancer or pancreatic cancer for instance.

P53
Location
17p13
DNA / RNA
11 exons.

Protein
The tumor suppressor gene P53 encodes a ubiquitous nuclear protein involved in the control of genome integrity by preventing cells from dividing before DNA damage is repaired; it has 5 conserved regions containing a transactivation domain, a DNA-binding domain, a tetramerization domain.

Somatic mutations
20-25% of breast cancers show P53 mutations and these correspond to aggressive breast tumors (loss of estrogen receptor expression).
90% of P53 mutations are found within exons 5 through 9, portions correspondig to codons 165-185 (exon 5) and 235-252 (exon 7) concentrating 50% of the mutations (mutational hot spots); most frequently involved are codons 175, 248 and 273; mutations affecting residues 165-185 and 235-252 bear worse prognostic significance than others; these amino acid residues are located in the L2 and L3 domains of the p53 protein; both these domains bind a Zinc atom and convey contact to DNA; it may thus be of greater phenotypic significance.
The majority of P53 mutations (80%) in breast cancer are missense, while nonsense mutations, deletions, insertions or, splice site mutations, which result in the truncation of the protein, make the rest (20%). Prolonged half-life of the protein can also be detected by immunohistochemistry and shows correlation with missense mutations.
**ERBB2**

**Location**
17q21.2

**Protein**
The ERBB2 (also called HER2 or NEU) gene encodes an integral type I protein of 185 kDa with a cysteine-rich extracellular region, a transmembrane domain and an intracellular region endowed with a tyrosine kinase activity.

**Somatic mutations**
Amplification: the ERBB2 gene is amplified and overexpressed in 20-25% of breast tumors; tumors showing ERBB2 amplification have predominantly lost estrogen receptor expression (ER-) and are of ductal invasive type; interestingly, 70% of intraductal comedo carcinomas show ERBB2 expression, suggesting a role of this gene in the etiology of this breast tumor subtype. Although ERBB2 amplification and overexpression are related to a worsened course of the disease, they do not represent independent prognostic indicators. However, the p185-ERBB2 protein being a transmembrane receptor with low levels of expression in normal tissues has turned out to be a very interesting target for therapeutical approaches; several protocols using engineered anti-ERBB2 antibodies have shown a good success rate.

**CCND1**

**Location**
11q13.3

**Protein**
The CCND1 gene codes for a cell cycle protein specifically acting in the G1 phase; upon interaction with cyclin dependent kinases (CDK4 or CDK6) cyclin D1 phosphorylates the p105-RB protein and thereby promotes progression in late G1 thus favoring entry into S phase; ectopic overexpression of CCND1 has been shown to result in shortened G1 phase and increased genetic instability, possibly due to a bypass of cell cycle checkpoints.

**Somatic mutations**
Amplification: the CCND1 gene is amplified in approximately 15% breast cancers; CCND1 amplification is strongly correlated to expression of ER and is prevalent in invasive lobular carcinomas; univariate analysis and Cox model studies show that CCND1 amplification is an independent prognostic factor, however, it bears greatest significance in node positive patients.

**FGFR1**

**Location**
8p11-12

**Protein**
The FGFR1 gene encodes an integral type I protein of 145 kDa with an extracellular region made of three immunoglobulin-like domains, a transmembrane domain and an intracellular region endowed with a tyrosine kinase activity; alternative splicing create a large number of isoforms; it is a receptor for different members of the fibroblast growth factor family (FGF), which has about 20 members known to date.

**Somatic mutations**
Amplification: the 8p11-12 region is amplified in about 10% of breast carcinomas; the FGFR1 gene is overexpressed as a consequence of the amplification, and is a good candidate for being the driver gene of the 8p11-12 amplicon; FGFR1 is frequently amplified concomitantly with CCND1 (40% of FGFR1 amplified tumors also show CCND1 amplification); this coamplification of FGFR1 and CCND1 chromosomal regions results in the formation of a hybrid chromosomal structure in which amplified FGFR1 and CCND1 sequences are sequentially arranged.

**BRCA1**

**Location**
17q21

**DNA / RNA**
Large gene of 22 coding exons spanning more than 70 kb of genomic DNA; exon 11 corresponds to almost 50% of the total coding sequence (5592 nucleotides); the BRCA1 mRNA has a size of 7.8 kb, and a complex pattern of alternative splicing has been reported; it is expressed in numerous tissues (breast, ovary, testis, spleen, thymus ...).

**Protein**
The corresponding protein has 1863 amino acids, and 190-220 kDa; BRCA1 is not a member of any known gene family; there is only two stretches of evolutionary conserved sequences between humans and mice: at the N-terminus (the RING finger motif), and at the C-terminus (the BRCT domain); the function of BRCA1 is still unknown but it seems to act as a tumor suppressor gene with transcriptional activity; it is involved in cell proliferation processes of mammary epithelial cells in response to hormonal stimulation, in apoptosis, control of recombination and genome integrity after binding to proteins involved in these activities.

**Germinal mutations**
More than 300 sequence variations at the germline level have been reported; a list is available on the BIC website:
http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/.
The germinal mutations are dispersed throughout the coding sequence; although a majority of these variations are unique, recurrent mutations such as 185delAG and 5382insC are observed; they were initially described in the Ashkenazy Jewish population; more than 80% of the sequence variants lead to a truncated protein; in contrast, the majority of missense mutations are of unknown clinical significance, excepted those in the RING finger region; in the BRCA1 families, an excess of breast, ovarian, and prostate cancers are seen; all mutations combined, penetrance at age 70 years works out at 56% to 87% in...
the case of breast cancer, and 16% to 63% % in that of ovarian cancer.
BRCA1-associated breast cancers have specific morphological features; they are more frequently of histoprognostic grade 3, highly proliferating and poorly differentiated tumors with a very pleomorophic nuclear pattern; high frequencies of P53 alterations and negativity of steroid receptors are found in these tumors; a high rate of medullary breast carcinomas is observed among BRCA1-associated breast cancers; evidence for possible genotype-phenotype correlations have been provided concerning the tumor spectrum (breast/ovarian cancer incidence rate), the penetrance, and the proliferation rate of tumors.

**Somatic mutations**
In contrast, somatic mutations of BRCA1 coding sequence are rare in breast/ovarian cancers.

**BRCA2**

**Location**
13q12-13

**DNA / RNA**
Like BRCA1 it is a large gene spanning more than 70 kb of genomic DNA; the coding sequence comprises 26 exons (10254 nucleotides) with three large ones (exons 10, 11, 27); the mRNA is of 11-12 Kb long; like BRCA1, it is expressed in various tissues.

**Protein**
The corresponding protein has 3418 amino acid residues (384 kDa), and is poorly conserved, except for the BRC repeats region in exon 11 (8 copies of 20-30 aa); like BRCA1, its function remains unknown; however, it acts as a tumor suppressor gene; transcriptional activation properties have been reported as well as involvement in the DNA repair system.

**Germlinal mutations**
More than 100 unique germ-line mutations are reported and are dispersed throughout the coding sequence (cf the BIC website, address above); recurrent mutations are seen: 6174delT (of Ashkenazy Jewish origin), 999del5 (Icelandic), and 6503delTT (in France and in the UK); the majority lead to a truncated protein and are considered as disease-associated mutations, except for a polymorphic stop codon in exon 27; nonsense mutations are of uncertain clinical significance.

BRCA2 germline mutations are associated with a high risk of male and female breast cancer; initially, the breast cancer risk was considered as equivalent to that of BRCA1, but in a recent work based only on the Icelandic recurrent BRCA2 999del5 mutation, the estimated risk of breast cancer at age 70 years is considered of only 37%; the ovarian cancer risk is lower than that of BRCA1; in addition, an excess of prostate and pancreas cancers is also seen.

At the morphological level, BRCA2 breast cancers seem to be different from both BRCA1-associated breast cancers and sporadic cases, with a poor differentiation but no high proliferation rate; evidence for possible genotype-phenotype correlation has been provided concerning the tumor spectrum (breast/ovarian cancer incidence rate).

**Somatic mutations**
Somatic mutations of BRCA2 coding sequence are rare in breast/ovarian cancers.

**BRCA3**

**Location**
An important breakthrough in the understanding of breast carcinogenesis came with the identification of the two major genes BRCA1 and BRCA2, corresponding to 52% and 32% of hereditary breast cancer families, respectively; however, the germline mutations of these genes do not account for all familial cases; additional genes may be involved.

One such gene might be located on chromosome arm 8p; a positive linkage has first been found in a small set of French families, and then a lod score of almost 3 was obtained in one German family; in addition, the chromosome 8p12-22 region seems to be frequently involved in breast carcinogenesis as well as in different types of tumors (lung, prostate, ovarian); while the 8p12-22 region remain a strong candidate locus, whole-genome linkage studies are in progress to identify the other gene(s) that predispose to breast cancer.

**PTEN**

**Location**
10q23

**DNA / RNA**
9 exons.

**Protein**
The PTEN protein (also called MMAC1) is an evolutionary conserved dual-specificity phosphatase sharing extensive similarity with the cytoskeletal protein tensin; PTEN appears to be a tumor suppressor since biallelic inactivations are observed in several types of tumors; inactivating germline mutations are responsible for a cancer prone syndrome, the Cowden disease (see below); also, PTEN -/- ES cells are highly tumorigenic in syngeneic mice whereas PTEN +/- are not.

**Germlinal mutations**
Heterozygous germline mutations are responsible for the Cowden disease, a cancer prone syndrome with high susceptibility to breast carcinoma, and, to a lesser degree, to thyroid carcinoma; most of the mutations are inactivating mutations, either by leading to protein truncation, or by introducing alterations in the phosphatase catalytic domain; germline mutations are also seen in the Bannayan-Riley-Ruvalcaba syndrome.

**Somatic mutations**
In spite of the initial description of PTEN homozygous deletion in two breast tumor xenografts and biallelic inactivation of PTEN in two breast carcinoma cell lines, very few PTEN mutations have been observed in sporadic breast carcinoma (1 described mutation in more than 100 analyzed tumors).
**ATM**

**Location**
11q23

**DNA / RNA**
The ATM gene covers 150 kb of DNA and is spread over 64 exons. It codes for a 13,000 bp transcript, translated into a 3500 aa protein.

**Protein**
Nuclear protein showing homology at its carboxy terminus with PI-3 kinase; belongs to a family of DNA damage signaling proteins characterized in either yeast or Drosophila; ATM interacts with the ABL protein and is known to transmit a signal to the P53 protein. ATM activity seems restricted to double strand DNA breaks induced by ionising radiations or radio-mimetics; it is noteworthy that the phenotype of Atm KO mice is very similar to that of ATM patients, but that heterozygous Atm +/- mutant mice do not show an increased incidence of cancer.

**Germlinal mutations**

The ATM gene is the genetic determinant to ataxia telangiectasia, a rare recessive disorder, which among other clinical signs, is characterized by an extreme sensitivity to ionising radiations; it has been hypothesized that ATM could play a role in cancer predisposition because AT patients show a 100 fold increased risk of cancer, particularly hematological malignancies; furthermore, epidemiological studies have suggested that AT heterozygotes were also at increased risk of developing cancer, specially breast cancer in women; this, added to the fact that the ATM gene maps to 11q23, a region frequently affected by losses of heterozygosity, suggested that heterozygous mutations in the ATM gene may favor breast cancer development; ATM heterozygotes have been estimated to represent 1% of the total population. Most mutations reported in ATM kindreds result in the truncation of the protein.

**Mismatch repair genes:**
- **MSH2 (2p21), MLH1 (3p21), PMS1 (2q31-33), PMS2/GTBP/MSH6 (7p22), MSH3 (5q)**

**Protein**
The proteins encoded by the mismatch repair genes are analogues of the bacteria Mut HLS system which is involved in the repairation of DNA replication errors; their defect leads to genomic instability, the most visible consequence of which is the presence of additional alleles at microsatellite marker; the latter are prone to replication errors; their alteration is a hallmark of genomic instability, also called RER (replication error) or MSI (microsatellite instability) phenotype.

**Somatic mutations**
Frequencies of genomic instability varies from 0 to 40% in breast cancer, depending on studies; however, mutations of mismatch repair genes are uncommon in breast cancer; thus, the high frequencies observed may be due to unknown genes involved in the control of DNA integrity.

**E-Cadherin**

**Location**
16q22.1

**Somatic mutations**
Mutations and loss of expression of the E-cadherin gene, located on chromosome arm 16q, is very frequently observed in breast lobular carcinomas.

**References**


Bertwistle D, Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev. 1998 Feb;8(1):14-20

